Severe or lethal toxicities with nucleosidic analogs: Time for action

Pharmacogenomics

Volumn 14, Issue 3, 2013, Pages 227-230

  Evrard, Alexandre ^a   Lacarelle, Bruno ^b   Ciccolini, Joseph ^b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

capecitabine; CDA; cytidine deaminase; gemcitabine; nucleosidic analogs; pharmacogenetics; toxicity

Indexed keywords

AZACITIDINE; CAPECITABINE; CARBOPLATIN; CYTARABINE; CYTIDINE DEAMINASE; FLUOROURACIL; GEMCITABINE; NUCLEOSIDE DERIVATIVE;

DRUG DISPOSITION; DRUG FATALITY; DRUG METABOLISM; DRUG TOXICITY; GENE FREQUENCY; GENE MUTATION; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; PANCREAS CANCER; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

ANIMALS; CYTIDINE DEAMINASE; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NUCLEOSIDES;

EID: 84873690204     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.208     Document Type: Review

References (20)

1. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer 9(4), 224-228 (2010).
2. Gilbert JA, Salavaggione OE, Ji Y et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12(6), 1794-1803 (2006).
3. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am. J. Clin. Oncol. 25(1), 96-100 (2002).
4. Yonemori K, Ueno H, Okusaka T et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res. 11(7), 2620-2624 (2005).
5. Mercier C, Raynal C, Dahan L et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet. Genomics 17(10), 841-844 (2007).
6. Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25(1), 32-42 (2007).
7. Maring JG, Wachters FM, Slijfer M et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur. J. Clin. Pharmacol. 66(6), 611-617 (2010).
8. Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J. 12(5), 395-403 (2012).
9. Ciccolini J, Dahan L, Andre N et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28(1), 160-165 (2010).
10. Ciccolini J, Mercier C, Dahan L, Andre N. Integrating pharmacogenetics into gemcitabine dosing - time for a change? Nat. Rev. Clin. Oncol. 8(7), 439-444 (2011).
11. Raynal C, Ciccolini J, Mercier C et al. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. Ther. Drug Monit. 32(1), 53-60 (2010).
12. Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14(6), 1797-1803 (2008).
13. Dahan L, Ciccolini J, Mercier C et al. Treatment failure upon gemcitabine intake. Is cytidine deaminase extensivity the ideal culprit? J. Clin. Oncol. 28(Suppl.) Abstract e14558 (2010).
14. Mahlknecht U, Dransfeld Cl, Bulut N et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 23(10), 1929-1932 (2009).
15. Abraham A, Varatharajan S, Abbas S et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 13(3), 269-282 (2012).
16. Ciccolini J, Evrard A, M'Batchi L et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 13(4), 393-397 (2012).
17. Serdjebi C, Ciccolini J, Evrard A et al. Severe toxicities in patients undergoing gemcitabine, ARA-C, capecitabine, or azacytidine treatments: is deregulated cytidine deaminase the bad guy. Cancer Res. 72(8 Suppl. 1) Abstract 1869 (2012).
18. Mercier C, Dupuis C, Blesius A et al. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother. Pharmacol. 63(6), 1177-1180 (2009).
19. Caronia D, Martin M, Sastre J et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin. Cancer Res. 17(7), 2006-2013 (2011).
20. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet. 119(3), 276-283 (2006).